Published in PLoS One on January 11, 2013
Serum complement C4a and its relation to liver fibrosis in children with chronic hepatitis C. World J Hepatol (2013) 0.79
Serum Inter-Alpha-Trypsin Inhibitor Heavy Chain 4 (ITIH4) in Children with Chronic Hepatitis C: Relation to Liver Fibrosis and Viremia. Hepat Res Treat (2014) 0.79
Chronic hepatitis C virus infection: Serum biomarkers in predicting liver damage. World J Gastroenterol (2016) 0.77
miR-150 Deficiency Protects against FAS-Induced Acute Liver Injury in Mice through Regulation of AKT. PLoS One (2015) 0.75
Microsomal prostaglandin E synthase-1 protects against Fas-induced liver injury. Am J Physiol Gastrointest Liver Physiol (2016) 0.75
Cell death: the significance of apoptosis. Int Rev Cytol (1980) 24.88
Diagnosis, management, and treatment of hepatitis C: an update. Hepatology (2009) 22.53
Apoptosis in the pathogenesis and treatment of disease. Science (1995) 20.24
Liver biopsy. N Engl J Med (2001) 9.91
The global burden of hepatitis C. Liver Int (2009) 8.89
Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol (2002) 8.21
Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology (2002) 6.92
Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease. J Hepatol (2003) 5.17
Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology (2009) 4.82
In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology (2006) 4.60
Evaluation of liver fibrosis: a concise review. Am J Gastroenterol (2004) 4.37
Noninvasive assessment of liver fibrosis. Hepatology (2010) 3.86
Biopsy and non-invasive methods for the diagnosis of liver fibrosis: does it take two to tango? Gut (2010) 2.70
Apoptosis: the nexus of liver injury and fibrosis. Hepatology (2004) 2.70
Prospective biopsy-controlled evaluation of cell death biomarkers for prediction of liver fibrosis and nonalcoholic steatohepatitis. Hepatology (2011) 2.49
Detection of apoptotic caspase activation in sera from patients with chronic HCV infection is associated with fibrotic liver injury. Hepatology (2004) 2.41
Cell death by apoptosis: basic concepts and disease relevance for the gastroenterologist. Gastroenterology (1996) 2.23
Diagnosis and quantitation of fibrosis. Gastroenterology (2008) 2.20
An apoptosis panel for nonalcoholic steatohepatitis diagnosis. J Hepatol (2011) 1.98
Liver biopsy:complications and risk factors. World J Gastroenterol (1999) 1.91
The impact of liver disease aetiology and the stages of hepatic fibrosis on the performance of non-invasive fibrosis biomarkers: an international study of 2411 cases. Aliment Pharmacol Ther (2011) 1.73
Non invasive fibrosis biomarkers reduce but not substitute the need for liver biopsy. World J Gastroenterol (2006) 1.63
Role of liver biopsy in management of chronic hepatitis C: a systematic review. Hepatology (2002) 1.51
Soluble forms of extracellular cytokeratin 18 may differentiate simple steatosis from nonalcoholic steatohepatitis. World J Gastroenterol (2007) 1.50
Apoptosis and hepatobiliary disease. Hepatology (1995) 1.39
Variability of the area under the receiver operating characteristic curves in the diagnostic evaluation of liver fibrosis markers: impact of biopsy length and fragmentation. Aliment Pharmacol Ther (2007) 1.38
Hepatitis C virus infection and apoptosis. World J Gastroenterol (2007) 1.36
Trends and projections of hepatitis C virus epidemiology in Latin America. Liver Int (2011) 1.31
Apoptosis in hepatitis C virus infection. Cell Death Differ (2003) 1.28
Mechanisms of Disease: HCV-induced liver injury. Nat Clin Pract Gastroenterol Hepatol (2007) 1.22
Caspase activation correlates with the degree of inflammatory liver injury in chronic hepatitis C virus infection. Hepatology (2001) 1.19
Biomarkers as a first-line estimate of injury in chronic liver diseases: time for a moratorium on liver biopsy? Gastroenterology (2005) 1.13
Apoptosis and liver disease. Am J Med (2000) 1.13
Serum levels of CK18 M30 and leptin are useful predictors of steatohepatitis and fibrosis in paediatric NAFLD. J Pediatr Gastroenterol Nutr (2010) 1.13
Fas / FasL system, IL-1beta expression and apoptosis in chronic HBV and HCV liver disease. J Viral Hepat (2008) 1.11
Immunopathogenesis of hepatitis C virus infection: multifaceted strategies subverting innate and adaptive immunity. Intern Med (2006) 1.11
The extent of liver steatosis in chronic hepatitis C virus infection is mirrored by caspase activity in serum. Hepatology (2005) 1.10
Chronic hepatitis C virus infection in children. J Pediatr Gastroenterol Nutr (2010) 1.09
The role of serum biomarkers in predicting fibrosis progression in pediatric and adult hepatitis C virus chronic infection. PLoS One (2011) 1.02
Apoptosis in liver diseases--detection and therapeutic applications. Med Sci Monit (2005) 1.02
Noninvasive assessment of hepatic fibrosis and necroinflammatory activity in Egyptian children with chronic hepatitis C virus infection using FibroTest and ActiTest. Eur J Gastroenterol Hepatol (2010) 0.98
Serum apoptotic caspase activity in chronic hepatitis C and nonalcoholic Fatty liver disease. J Clin Gastroenterol (2010) 0.97
A comparison of four fibrosis indexes in chronic HCV: development of new fibrosis-cirrhosis index (FCI). BMC Gastroenterol (2011) 0.96
The nature of piecemeal necrosis in chronic active hepatitis. Lancet (1979) 0.95
Cytokeratin-18 and hyaluronic acid levels predict liver fibrosis in children with non-alcoholic fatty liver disease. Acta Biochim Pol (2011) 0.93
Serum levels of soluble Fas, soluble tumor necrosis factor-receptor II, interleukin-2 receptor and interleukin-8 as early predictors of hepatocellular carcinoma in Egyptian patients with hepatitis C virus genotype-4. Comp Hepatol (2010) 0.91
Serum concentration of sFas and sFasL in healthy HBsAg carriers, chronic viral hepatitis B and C patients. World J Gastroenterol (2004) 0.89
Circulating and hepatic Fas expression in HCV-induced chronic liver disease and hepatocellular carcinoma. Medscape J Med (2008) 0.89
Noninvasive diagnosis of liver fibrosis in patients with HIV infection and HCV/HBV co-infection. J Viral Hepat (2009) 0.88
Combined use of aspartate aminotransferase, platelet count and matrix metalloproteinase 2 measurements to predict liver fibrosis in HIV/hepatitis C virus-coinfected patients. HIV Med (2011) 0.88
Role of serum soluble Fas/soluble Fas ligand and TNF-alpha on response to interferon-alpha therapy in chronic hepatitis C. Liver (2000) 0.88
Apoptosis markers related to pathogenesis of pediatric chronic hepatitis C virus infection: M30 mirrors the severity of steatosis. J Med Virol (2010) 0.88
A brief review on molecular, genetic and imaging techniques for HCV fibrosis evaluation. Virol J (2011) 0.85
Characterization of soluble FAS, FAS ligand and tumour necrosis factor-alpha in patients with chronic HCV infection. J Clin Virol (2005) 0.84
Elevated serum soluble Fas levels in the various stages of hepatitis C virus-induced liver disease. J Int Med Res (2003) 0.83
Characterization of chronic HCV infection-induced apoptosis. Comp Hepatol (2011) 0.81
Clinical significance of serum soluble Fas, Fas ligand and fas in intrahepatic lymphocytes in chronic hepatitis C. Immunol Invest (2008) 0.81
Association among Fas expression in leucocytes, serum Fas and Fas-ligand concentrations and hepatic inflammation and fibrosis in chronic hepatitis C. Liver Int (2009) 0.80
Fas antigen (CD95) expression and apoptosis in hepatocytes of patients with chronic viral hepatitis. Eur J Gastroenterol Hepatol (2003) 0.80
Evaluation of FibroTest-ActiTest in children with chronic hepatitis C virus infection. Gastroenterol Clin Biol (2009) 0.80
Circulating soluble Fas levels in patients with hepatitis C virus infection and interferon therapy. J Gastroenterol (2004) 0.78
High sustained virologic response rates in children with chronic hepatitis C receiving peginterferon alfa-2b plus ribavirin. J Hepatol (2010) 2.01
Demonstration of Epstein-Barr virus in carcinomas of various sites. Cancer Res (2002) 1.88
Fulminant presentation of autoimmune hepatitis: clinical features and early predictors of corticosteroid treatment failure. Eur J Gastroenterol Hepatol (2015) 1.47
Gender susceptibility to chronic hepatitis C virus infection associated with interleukin 10 promoter polymorphism. J Virol (2006) 1.06
Serum creatinine and bilirubin predict renal failure and mortality in patients with spontaneous bacterial peritonitis: a retrospective study. Liver Int (2008) 1.05
The role of serum biomarkers in predicting fibrosis progression in pediatric and adult hepatitis C virus chronic infection. PLoS One (2011) 1.02
[Hepatic tuberculoma: presentation of cases and review of the literature]. Acta Gastroenterol Latinoam (2004) 0.92
Characterization of Epstein Barr virus latency pattern in Argentine breast carcinoma. PLoS One (2010) 0.90
Etiology of hepatocellular carcinoma in Argentina: results of a multicenter retrospective study. Acta Gastroenterol Latinoam (2009) 0.89
Apoptosis markers related to pathogenesis of pediatric chronic hepatitis C virus infection: M30 mirrors the severity of steatosis. J Med Virol (2010) 0.88
EBNA1 sequences in Argentinean pediatric acute and latent Epstein-Barr virus infection reflect circulation of novel South American variants. J Med Virol (2010) 0.88
Changing etiologies and outcomes of acute liver failure: perspectives from 6 transplant centers in Argentina. Liver Transpl (2014) 0.87
Genetic variation in interleukin-28B predicts SVR in hepatitis C genotype 1 Argentine patients treated with PEG IFN and ribavirin. Ann Hepatol (2011) 0.87
Characterization of the basal core promoter and precore regions in anti-HBe-positive inactive carriers of hepatitis B virus. Int J Infect Dis (2011) 0.86
Phylogenetic analysis of previously nontypeable hepatitis C virus isolates from Argentina. J Clin Microbiol (2006) 0.84
Hepatitis C virus infection in infants and children from Argentina. J Clin Microbiol (2004) 0.84
Structural variability of the carboxy-terminus of Epstein-Barr virus encoded latent membrane protein 1 gene in Hodgkin's lymphomas. J Med Virol (2007) 0.84
Epstein-Barr virus presence in pediatric diffuse large B-cell lymphoma reveals a particular association and latency patterns: analysis of viral role in tumor microenvironment. Int J Cancer (2012) 0.84
Hepatitis C virus isolates from Argentina disclose a novel genotype 1-associated restriction pattern. J Clin Microbiol (2004) 0.83
Dynamic changes in viral population structure and compartmentalization during chronic hepatitis C virus infection in children. Virology (2013) 0.83
Granulomatous nephritis associated with R334Q mutation in NOD2. J Rheumatol (2007) 0.82
Lack of evidence for an association of Epstein-Barr virus infection with breast carcinoma--another point of view. Breast Cancer Res (2003) 0.82
Full-length genome characterization of hepatitis B virus genotype H strain isolated from serum samples collected from two chronically infected patients in Argentina. J Clin Microbiol (2009) 0.82
Naturally occurring hepatitis B virus (HBV) variants with primary resistance to antiviral therapy and S-mutants with potential primary resistance to adefovir in Argentina. Antiviral Res (2010) 0.82
Epstein-Barr virus BZLF1 gene promoter variants in pediatric patients with acute infectious mononucleosis: its comparison with pediatric lymphomas. J Med Virol (2009) 0.81
Hereditary nonpolyposis colorectal cancer (Lynch Syndrome) in Argentina: report from a referral hospital register. Dis Colon Rectum (2007) 0.81
The role of innate cells is coupled to a Th1-polarized immune response in pediatric nonalcoholic steatohepatitis. J Clin Immunol (2012) 0.80
Comparison of Epstein-Barr virus presence in Hodgkin lymphoma in pediatric versus adult Argentine patients. Arch Pathol Lab Med (2003) 0.80
Epstein-Barr virus associated with primary CNS lymphoma and disseminated BCG infection in a child with AIDS. Int J Infect Dis (2005) 0.80
Assessment of Epstein-Barr virus association with pediatric non-hodgkin lymphoma in immunocompetent and in immunocompromised patients in Argentina. Arch Pathol Lab Med (2002) 0.80
Epstein Barr virus-associated lymphoma in HIV-infected children. Pathol Res Pract (2002) 0.80
[Latin American guideline for the treatment of chronic hepatitis B]. Acta Gastroenterol Latinoam (2007) 0.79
Neonatal cholestasis in congenital pituitary hormone deficiency and isolated hypocortisolism: characterization of liver dysfunction and follow-up. Arq Bras Endocrinol Metabol (2011) 0.79
Model for end-stage liver disease exceptions committee activity in Argentina: does it provide justice and equity among adult patients waiting for a liver transplant? HPB (Oxford) (2010) 0.79
Distinctive Epstein-Barr virus variants associated with benign and malignant pediatric pathologies: LMP1 sequence characterization and linkage with other viral gene polymorphisms. J Clin Microbiol (2012) 0.79
Cell cycle characteristics and Epstein-Barr virus are differentially associated with aggressive and non-aggressive subsets of Hodgkin lymphoma in pediatric patients. Leuk Lymphoma (2010) 0.78
[Clinical course of inflammatory bowel disease in patients transplanted for primary sclerosing cholangitis]. Acta Gastroenterol Latinoam (2008) 0.78
[Cost-effectiveness analysis of entecavir versus lamivudine in patients with chronic hepatitis B]. Acta Gastroenterol Latinoam (2008) 0.78
Pediatric Hodgkin lymphoma in 2 South American series: a distinctive epidemiologic pattern and lack of association of Epstein-Barr virus with clinical outcome. J Pediatr Hematol Oncol (2008) 0.78
Low frequency of Epstein Barr virus association and high frequency of p53 overexpression in an Argentinean pediatric T-cell lymphoma series. Pediatr Dev Pathol (2009) 0.77
[Argentine consensus on hepatitis C 2013]. Acta Gastroenterol Latinoam (2014) 0.77
Apoptosis markers in liver biopsy of nonalcoholic steatohepatitis in pediatric patients. Hum Pathol (2008) 0.76
Intraparenchymal intracranial pressure monitoring in patients with acute liver failure. Arq Neuropsiquiatr (2008) 0.76
[Recommendations for the treatment of chronic genotype 1 hepatitis C virus infection]. Acta Gastroenterol Latinoam (2012) 0.76
Epstein-Barr virus (EBV) association and latency profile in pediatric Burkitt's lymphoma: experience of a single institution in Argentina. J Med Virol (2013) 0.76
Caffeic Acid Phenylethyl Ester and MG-132 Have Apoptotic and Antiproliferative Effects on Leukemic Cells But Not on Normal Mononuclear Cells. Transl Oncol (2009) 0.76
An update on the management of hepatitis C: guidelines for protease inhibitor-based triple therapy from the Latin American Association for the Study of the Liver. Ann Hepatol (2013) 0.76
No Influence of bcl-2, p53, and p21waf1 protein expression on the outcome of pediatric Hodgkin lymphomas. J Pediatr Hematol Oncol (2006) 0.76
LMP1 promoter sequence analysis in Epstein Barr virus pediatric infection reveals preferential circulation of B95.8 related variants in Argentina. Infect Genet Evol (2013) 0.76
Colorectal cancer staging: reappraisal of N/PN classification. Dis Colon Rectum (2004) 0.76
The most severe forms of type I autoimmune hepatitis are associated with genetically determined levels of TGF-beta1. Clin Immunol (2009) 0.76
[Twenty-four weeks therapy with peginterferon alfa-2a could be similar to 48 weeks therapy in patients with HBeAg positive chronic hepatitis B and good predictors of response: results of a pilot study]. Acta Gastroenterol Latinoam (2009) 0.75
Short communication: fasting increases serum concentrations of bilirubin in patients receiving atazanavir: results from a pilot study. AIDS Res Hum Retroviruses (2012) 0.75
Early predictors of renal dysfunction in cirrhotic patients after liver transplantation. Acta Gastroenterol Latinoam (2014) 0.75
[Transient elastography: noninvasive assessment of liver fibrosis. Report of 1,000 cases in Argentina]. Acta Gastroenterol Latinoam (2012) 0.75
Germline TP53 mutations and single nucleotide polymorphisms in children. Medicina (B Aires) (2009) 0.75
[Latin American guideline for the management of chronic hepatitis B]. Acta Gastroenterol Latinoam (2011) 0.75
[Treatment in transplant patients]. Acta Gastroenterol Latinoam (2005) 0.75
[80 years of the Argentine Society of Gastroenterology]. Acta Gastroenterol Latinoam (2007) 0.75
[Structural and functional polarity of porcine hepatocyte cultured spheroids]. Acta Gastroenterol Latinoam (2006) 0.75
Diagnosis of patients with suspected chronic hepatitis C infection. Ann Hepatol (2010) 0.75
[Non biological artificial devices: what do they mean and what is their role today?]. Acta Gastroenterol Latinoam (2012) 0.75
Screening for liver cancer during transplant waiting list: a multicenter study from South America. Eur J Gastroenterol Hepatol (2015) 0.75
[Regenerative nodular hyperplasia in HIV]. Acta Gastroenterol Latinoam (2011) 0.75
[Image in gastric antrum]. Acta Gastroenterol Latinoam (2012) 0.75
[The Argentine experience with human immune deficiency virus positive patients in the waiting list for liver transplantation: preliminary analysis]. Acta Gastroenterol Latinoam (2013) 0.75
[Argentine consensus on hepatitis B]. Acta Gastroenterol Latinoam (2013) 0.75
[Immunohistochemical expression and microsatellite instability in Lynch syndrome]. Medicina (B Aires) (2007) 0.75
Molecular characterization of a novel splice site mutation within the CYBB gene leading to X-linked chronic granulomatous disease. Pediatr Blood Cancer (2005) 0.75
[Chronic hepatitis C. First treatment]. Acta Gastroenterol Latinoam (2005) 0.75
Immunohistochemical expression of p53, bcl-2, and p21waf1 in 48 Argentinean children with non-Hodgkin lymphoma. Appl Immunohistochem Mol Morphol (2006) 0.75
[Diagnosis, treatment and evolution of the Budd-Chiari syndrome: a single center experience]. Acta Gastroenterol Latinoam (2010) 0.75